Attending the breast screening programme after breast cancer treatment: A population-based study

2013 ◽  
Vol 37 (6) ◽  
pp. 968-972 ◽  
Author(s):  
Linda de Munck ◽  
Annemiek Kwast ◽  
Dick Reiding ◽  
Geertruida H. de Bock ◽  
Renée Otter ◽  
...  
The Breast ◽  
2016 ◽  
Vol 26 ◽  
pp. 80-86 ◽  
Author(s):  
Kaisu Ojala ◽  
Tuomo J. Meretoja ◽  
Johanna Mattson ◽  
Päivi Salminen-Peltola ◽  
Suvi Leutola ◽  
...  

JAMA Oncology ◽  
2019 ◽  
Vol 5 (2) ◽  
pp. 267 ◽  
Author(s):  
Anouk J. M. Rombouts ◽  
Jonathan Huising ◽  
Niek Hugen ◽  
Sabine Siesling ◽  
Philip Martin Poortmans ◽  
...  

1995 ◽  
Vol 2 (4) ◽  
pp. 195-199 ◽  
Author(s):  
W Scaf-Klomp ◽  
F L P van Sonderen ◽  
R Stewart ◽  
J A A M van Dijck ◽  
W J A van den Heuvel

Objective –To investigate changes in attendance over the course of a population based breast screening programme. Design – Longitudinal; analysis of registered data over nine screening rounds. Setting –Subjects belong to the screening population of the Nijmegen experimental breast screening programme (1975–1990). Subjects –A cohort of 6898 women who were enrolled in 1975 at the age of 50–69 years and who were invited to nine subsequent screening rounds, irrespective of their attendance at previous rounds. Results –Attendance of women aged 50–53 years at entry was high at the initial screening (88%), decreased in the course of the programme, but remained well over 60% until round 8; 39% completed nine rounds and 24% completed seven to eight rounds. Attendance of women who were older at entry was somewhat lower at the initial screening (87%–82%) and declined more strongly. Regular compliance was also lower. Specific compliance patterns are found that can be relevant for further research. Conclusions –A substantial proportion of eligible women can be committed to mammography every two years, possibly even after reaching the age of 70, if the age at entry is around 50 and the screening programme is well established in the community. Starting a screening programme in older women seems ineffective.


2005 ◽  
Vol 12 (4) ◽  
pp. 179-184 ◽  
Author(s):  
Gill Lawrence ◽  
Olive Kearins ◽  
Emma O'Sullivan ◽  
Nancy Tappenden ◽  
Matthew Wallis ◽  
...  

Objectives: To illustrate the ability of the West Midlands breast screening status algorithm to assign a screening status to women with malignant breast cancer, and its uses as a quality assurance and audit tool. Methods: Breast cancers diagnosed between the introduction of the National Health Service [NHS] Breast Screening Programme and 31 March 2001 were obtained from the West Midlands Cancer Intelligence Unit (WMCIU). Screen-detected tumours were identified via breast screening units, and the remaining cancers were assigned to one of eight screening status categories. Multiple primaries and recurrences were excluded. Results: A screening status was assigned to 14,680 women (96% of the cohort examined), 110 cancers were not registered at the WMCIU and the cohort included 120 screen-detected recurrences. Conclusions: The West Midlands breast screening status algorithm is a robust simple tool which can be used to derive data to evaluate the efficacy and impact of the NHS Breast Screening Programme.


2019 ◽  
Vol 121 (8) ◽  
pp. 719-721 ◽  
Author(s):  
Nadom Safi ◽  
Antoinette Anazodo ◽  
Jan E. Dickinson ◽  
Kei Lui ◽  
Alex Y. Wang ◽  
...  

BMJ ◽  
2020 ◽  
pp. m1570 ◽  
Author(s):  
Gurdeep S Mannu ◽  
Zhe Wang ◽  
John Broggio ◽  
Jackie Charman ◽  
Shan Cheung ◽  
...  

AbstractObjectiveTo evaluate the long term risks of invasive breast cancer and death from breast cancer after ductal carcinoma in situ (DCIS) diagnosed through breast screening.DesignPopulation based observational cohort study.SettingData from the NHS Breast Screening Programme and the National Cancer Registration and Analysis Service.ParticipantsAll 35 024 women in England diagnosed as having DCIS by the NHS Breast Screening Programme from its start in 1988 until March 2014.Main outcome measuresIncident invasive breast cancer and death from breast cancer.ResultsBy December 2014, 13 606 women had been followed for up to five years, 10 998 for five to nine years, 6861 for 10-14 years, 2620 for 15-19 years, and 939 for at least 20 years. Among these women, 2076 developed invasive breast cancer, corresponding to an incidence rate of 8.82 (95% confidence interval 8.45 to 9.21) per 1000 women per year and more than double that expected from national cancer incidence rates (ratio of observed rate to expected rate 2.52, 95% confidence interval 2.41 to 2.63). The increase started in the second year after diagnosis of DCIS and continued until the end of follow-up. In the same group of women, 310 died from breast cancer, corresponding to a death rate of 1.26 (1.13 to 1.41) per 1000 women per year and 70% higher than that expected from national breast cancer mortality rates (observed:expected ratio 1.70, 1.52 to 1.90). During the first five years after diagnosis of DCIS, the breast cancer death rate was similar to that expected from national mortality rates (observed:expected ratio 0.87, 0.69 to 1.10), but it then increased, with values of 1.98 (1.65 to 2.37), 2.99 (2.41 to 3.70), and 2.77 (2.01 to 3.80) in years five to nine, 10-14, and 15 or more after DCIS diagnosis. Among 29 044 women with unilateral DCIS undergoing surgery, those who had more intensive treatment (mastectomy, radiotherapy for women who had breast conserving surgery, and endocrine treatment in oestrogen receptor positive disease) and those with larger final surgical margins had lower rates of invasive breast cancer.ConclusionsTo date, women with DCIS detected by screening have, on average, experienced higher long term risks of invasive breast cancer and death from breast cancer than women in the general population during a period of at least two decades after their diagnosis. More intensive treatment and larger final surgical margins were associated with lower risks of invasive breast cancer.


Sign in / Sign up

Export Citation Format

Share Document